Bayer (OTCPK:BAYR.Y) FY Earnings Call Presentation

44th Annual J.P. Morgan Healthcare Conference Stefan Oelrich Member Of The Board Of Management Of Bayer AG President Pharmaceuticals January 13th, 2026 Our Strategy is Showing Tangible Results Nubeqa and Kerendia with sustained growth momentum, offsetting Xarelto declines Next wave of growth with Beyonttra, Lynkuet and Asundexian Robust Eylea Franchise and Foundational Business Driver for near-term growth Renew topline Grow pipeline value New Innovation Model yielding success Five new indications or product ...